**Antenatal care service delivery and factors affecting effective tetanus vaccine coverage in low- and middle-income countries: results of the Maternal Immunisation and Antenatal Care Situational Analysis (MIACSA) project**

Authors: Giles ML1, Mason E2, Muñoz FM3, Moran AC4, Lambach P5, Merten S6, Diaz T4, Baye M7, Mathai M8, Pathirana J9, Rendell S10, Tunçalp Ö, Hombach J5, Roos N11

Affiliations

1 Associate Professor, Department of Obstetrics and Gynaecology, Monash University, Melbourne, Australia

2 Hon Professor, London School of Hygiene and Tropical Medicine, London, UK

3 Associate Professor of Pediatrics, Section Infectious Diseases, Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA

4 Epidemiology, Monitoring and Evaluation (EME), Department of Maternal, Newborn, child and adolescent health (MCA), World Health Organization, Geneva, Switzerland

5 Department of Immunization, Vaccines and Biologicals (IVB), World Health Organization, Geneva, Switzerland

6 Swiss Tropical and Public Health Institute and University of Basel, Basel , Switzerland

7 Coordinator of the National program to combat maternal, newborn and child mortality, Ministry of Public Health, Cameroon

8 Department of International Public Health, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.

9 Medical Research Council: Respiratory and Meningeal Pathogens Research Unit and Department of Science and Technology/ National Research Foundation: Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg

10 MD/PhD Candidate, Department of Anthropology, University of Pennsylvania, Philadelphia, USA

11 Karolinska Institutet, Department of Medicine, Clinical Epidemiology Division, Stockholm, Sweden

Author for correspondence:

Dr Michelle Giles

Infectious Diseases Physician

Department of Obstetrics and Gynaecology

Monash University

Abstract: (Max 300 words, currently 300)

**Objectives:** To map the integration of existing maternal tetanus immunization programmes for pregnant women in low- and middle-income countries (LMICs) within antenatal care services and to identify and understand the challenges, barriers and facilitators associated with high performance maternal vaccine service delivery in LMICs.

**Design:** A mixed methods, cross sectional study with four data collection phases including a desk review, online survey, telephone and face-to-face interviews and in country visits. Associations of different service delivery process components with protection at birth (PAB) and with country groups were established. Regression analysis and structural equation modelling was used to assess associations of different variables with maternal tetanus immunization. Latent class analysis (LCA), was used to group countries based on several indicators, and to address the problem of multicollinearity.

**Setting:** LMICs

**Results:** The majority of LMICs have a policy on recommended number of ANC visits, however most have yet to implement the WHO guidelines recommending eight ANC contacts. Countries recommending >4 ANC contacts were more likely to have high (PAB) >90% and were more likely to have high potential for protection of mothers and their young children from vaccine-preventable infections. Passive disease surveillance was the most common form of disease surveillance performed but morbidity and mortality indicators recorded differed between countries. The presence of user fees was significantly associated with lower PAB.

**Conclusions:** Recommendations include increasing the number of contacts with pregnant women by implementing the current WHO ANC guidelines to facilitate increased opportunities for vaccination during each pregnancy. Improved utilisation of ANC services by increasing the demand side (for example by increasing the quality of services, reducing any associated costs and supporting user fee exemptions for all vulnerable women) or the supply side can also enhance utilisation of ANC services which are positioned as an ideal platform for delivery of maternal vaccines.

Key Words: Pregnancy, antenatal care, tetanus, vaccination, MIACSA

Funding: The Bill and Melinda Gates foundation has funded WHO to conduct this work. Grant number: OPP1156378

Acknowledgements

The investigators wish to thank the EPI and MNCH focal points at the regional and national WHO offices for their helpful contributions to the planning of the study, and the external specialists of the Expert Advisory Panel for their valuable advice and guidance on the development of the protocol methodology.

Members of the Expert Advisory Panel: Mercy Ahun, Martina Baye, Pradeep Haldar and Veena Dhawan, Michelle L Giles (co-chair), Matthews Mathai, Flor M Muñoz (chair)

Consultants: Carsten Mantel, Elizabeth Mason, Sonja Merten, Jayani Pathirana, Sara Rendell

Competing Interests Statement: no conflicts of interest declared by any of the authors

Diaz T, Hombach J, Lambach P, Moran A, Nic Lochlainn LM, Perut M, Tuncalp Mingard Ö, Yusuf N, are staff members of the World Health Organization. The views expressed in this publication are those of the authors and not necessarily those of the World Health Organization.

Author Contributions:

MG: main writer and editor of the manuscript

NR: design of study, interpretation of results, drafting and finalizing of the manuscript

SM: statistical analysis, development of tables and figures and interpretation of results

All authors: reviewed and approved the final manuscript

**Background**

In 2015, an estimated 303,000 women died from pregnancy-related causes (1), and 2.6 million babies were stillborn (2). In 2017 an estimated 2.5 million babies died in the first month of life (3). Many of these deaths would be preventable through increased access to and use of higher-quality health care during pregnancy and childbirth. Building on the progress made by the Millennium Development Goals (MDGs) in 2015, the Sustainable Development Goals (SDG) were launched to guide the eradication of poverty, hunger, illiteracy, and disease (4). The third SDG on good health and wellbeing, aims to end preventable deaths of newborns and children under five years of age by 2030, with a target to further reduce neonatal mortality to at least as low as 12 per 1,000 live births and under five mortality to at least as low as 25 per 1,000 live births (5). Infectious diseases, particularly pneumonia, sepsis and respiratory illness, are leading causes of death in children under 5 years of age (6), some of which may be preventable by maternal immunization.

Deaths during the neonatal period constitute almost 50% of the total deaths occurring in children under 5 years, with little progress made in the past decades (7). The Maternal Newborn Tetanus Elimination (MNTE) initiative, launched in 1989, was the first maternal immunization programme to be recommended globally (8). Along with safe birthing practices this has contributed to over 700,000 lives saved and as of today only 13 countries have yet to eliminate maternal and neonatal tetanus (8). Other vaccines being recommended during pregnancy include influenza and in many high-income settings pertussis (9-15). For vaccination to be an effective intervention strategy during pregnancy, it relies on maternity care providers recommending the intervention, women understanding and accepting the intervention, and vaccination of the pregnant woman.

Antenatal care (ANC) is accepted as the natural entry point for interventions during pregnancy, such as maternal immunization, and provides important opportunities for the prevention, identification and treatment of diseases affecting pregnant women and their babies. Despite progress made in ANC utilization, UNICEF estimates that in 2010-2016, only 61.8% of women globally received at least four antenatal care visits (16). This figure is even lower in regions with the highest rates of maternal and perinatal mortality, such as sub-Saharan Africa (52%) and South Asia (46%) (16). Not only is the number of contacts during pregnancy important but also the timing of the first ANC visit. Ensuring the first ANC visit is in the first trimester, is essential to optimising health outcomes for women and children. Global estimates between 1990-2013 report early ANC visit as 24% in low income countries compared to 82% in high income countries (17). In 2016, the World Health Organization (WHO) issued new recommendations to improve antenatal care and to reduce the risk of stillbirths and pregnancy complications (18). Central to these new recommendations is the focus on a minimum of eight contacts during pregnancy and one ultrasound scan before 24 weeks of gestation as well as a positive pregnancy experience, ensuring a healthy pregnancy for mother and baby leading to a positive birth and motherhood experience (18).

In addition to tetanus and influenza, there are new maternal vaccine candidates in discovery or development such as against respiratory syncytial virus (RSV) and group B streptococcus (GBS). In low- and middle-income countries RSV and GBS account for a significant burden of disease (19, 20). RSV is the most important cause of viral lower respiratory tract disease in infants globally. In a systematic review, it was estimated that in 2015 RSV infection was responsible for 33.1 million episodes of RSV acute lower respiratory infection, resulting in 1.4 million hospital admissions in children less than six months of age and 27,300 in-hospital deaths, a significant proportion of these in the first month of life (19). GBS is an important cause of neonatal sepsis and meningitis, particularly in the first 3 months of life. In 2015, there were an estimated 90,000 deaths in infants less than three months of age, 57,000 fetal infections/stillbirths (defined as birth of a fetus weighing >1000gm and/or >28 weeks gestational age with no signs of life) and 33,000 cases of invasive GBS disease in pregnant or post-partum women (including endometritis, chorioamnionitis and sepsis) (20).

If these vaccine candidates prove to be safe and efficacious they may be recommended for pregnant women in the future. In anticipation of this, there is an urgent need to describe the current landscape of antenatal care service provision and better understand the optimal ways to deliver vaccines, including the value of using antenatal care services as a delivery platform.

The WHO, supported by the Bill and Melinda Gates Foundation, commenced work in mapping strengths of existing maternal tetanus immunization programmes through the Maternal Immunization and Antenatal Care Situational Analysis (MIACSA) project. This project aims to identify and understand the challenges from, barriers to and facilitators of successful maternal immunization in LMICs (20). This project also sets out to develop a typology of existing health systems in terms of vaccine delivery strategies to pregnant women and the attributes associated with high performance maternal vaccine service delivery in LMICs. An important goal is to identify what aspects of antenatal care need to be strengthened and what gaps need to be addressed to inform the introduction of additional maternal vaccines particularly into antenatal care services.

**Methods**

*Study design and data collection*

A detailed overview of the project methodology has been published previously (21). In summary, between November 2016 and September 2018, a multi-method cross sectional study was carried out with four components. These four components are briefly summarised below.

1. Phase I - A desktop review of pre-defined maternal and child health indicators and World Bank Data for economic level in 137 low- and middle income countries (LMICs)

The following databases were used to extract data; Demographic and Health Surveys (DHS)/Multiple Indicator Cluster Surveys (MICS), WHO/United Nations Children’s Fund (UNICEF) estimates of national immunization coverage, WHO/UNICEF Joint Reporting Forms (JRF), Maternal Neonatal Tetanus Elimination (MNTE) database, WHO Maternal, Newborn, Child, and Adolescent Health (MNCAH) policy surveys, GAVI web page for eligibility, United Nations (UN) Inter-agency Group for Child Mortality Estimation, trends in maternal mortality: 1990 to 2015 and United Nations, Department of Economic and Social Affairs, Population Division. The number of countries in the databases and time periods reviewed varies. The information used in this analysis is based on the most recent surveys at the time of the analysis.

2. Phase II - Global online survey sent to 116 LMICs

An 18-item online survey was developed collecting data on service delivery models of maternal tetanus vaccination, programme funding, disease surveillance, vaccine safety surveillance and maternal vaccines other than tetanus. The WHO European Region opted out of the project given a lower priority of the MTNE initiative in this region.

3. Phase III - Telephone and face to face interviews

A 91-item survey was developed by the MIACSA Expert Advisory Panel. The telephone interview was pilot tested in two countries (Sri Lanka and Tanzania), and thereafter adapted based on participant comments and administered via in-depth telephone and face-to-face interviews with Expanded Programme on Immunisation (EPI) and Maternal, Newborn and Child health (MNCH) programme officers in a sample of countries. Data from the pilots was included in the final analysis.

4. Phase IV- In-country visits

In-country visits were conducted in ten selected countries. Countries were identified based on a system developed by the researchers to stratify countries into four groups according to maternal tetanus vaccination performance measured as protection at birth (PAB) and antenatal care performance (measured as ANC4+ coverage). A cut-off of PAB of 90% was used to divide countries into high and low maternal tetanus vaccination performers. For antenatal care performance, high and low performance was defined as either above or below the median ANC4+ coverage. The final country selection tried to ensure representation from all WHO regions, including high-performing countries, MNTE priority countries and countries with high ANC4+ coverage. Data collected included from in depth key informant interviews, focus group discussions, and health care facility observations.

*Key definitions*

**PAB**: is the proportion of neonates protected at birth against neonatal tetanus, by combining data on the number of tetanus vaccine doses received by the mother by the last baby born, interval between doses, and time since last dose (using card or verbal history).PAB was used as dichotomous variable: low: PAB<90% vs. high: PAB>=90%.

**ANC performance**: The proportion of pregnant women who attended at least one ANC visit during their last pregnancy (ANC1) and the proportion of pregnant women who attended four or more ANC visits during their last pregnancy (ANC4+) were used.

**EPI performance:** Data from the desk review on Diphtheria-Pertussis-Tetanus (DPT)/third dose of pentavalent (Penta3) vaccines were used.

*Statistical analysis*

All data were imported into STATA V.15 (StataCorp LCC, Texas) for analyses. All analyses were conducted using non-missing data. Summary measures (proportions, means, medians and standard errors) were obtained for all variables of interest.

### Countries were then grouped in two ways; (1) according to high and low-PAB coverage and (2) according to selected MNCH and EPI performance indicators. In order to create country groups based on a combination of MNCH and EPI performance indicators, latent class analysis (LCA), was used to enable the characterization of an unobserved (latent) variable through analysis of the structure of the relationship among several observed variables (22). LCA allowed multiple indicators to simultaneously contribute to the definition of country groups. LCA therefore was able to address the problem of multi-collinearity. The variables included in the LCA model included PAB, TT2+, DPT3, ANC1, ANC4+, neonatal mortality rate and maternal mortality rate. The LCA generated four country groups defined as;

Group 1: Currently ***very*** ***limited potential*** to protect mothers and their young children from vaccine-preventable infections (limited ANC and EPI performance)

Group 2: ***Limited potential*** to protect mothers and their young children from vaccine-preventable infections (moderate ANC and EPI performance)

Group 3: ***Moderate potential*** to protect of mothers and their young children from vaccine-preventable infections (mostly successful ANC and EPI performance)

Group 4: ***High potential*** for protection of mothers and their young children from vaccine-preventable infections (successful ANC and EPI performance)

Fisher’s exact test was used to establish differences in service delivery process components (1) by PAB coverage and (2) by country groups,

**Results**

The online survey (sent to 116 countries) was answered by 97 countries, of which two provided incomplete responses. Twenty-six countries participated in the telephone survey, and week-long in-country visits took place in ten countries. In each country 6-14 health facilities identified by the Ministry of Health were visited, leading to a total of 96 health facility visits and interviews with health facility managers. (Figure 1)

**Figure 1.** Four phases of the project and number of countries participating

Benin, Bhutan, Botswana, Cameroon, Democratic Republic of the Congo (DRC), Republic of Congo, Colombia, Costa Rica, Dominica, Egypt, Ethiopia, Fiji, Gabon, Malawi, Morocco, Nicaragua, Niger, Pakistan, Papua New Guinea, Senegal, Sierra Leone, South Sudan, Sri Lanka, Thailand, Tanzania, Uganda

Benin, Bhutan, Ethiopia, Fiji, Gabon, Morocco, Panama, Senegal, Tanzania and Thailand

10 LMICs

Phase IV

In country visits

97 responses

(two incomplete)

26 LMICs

116 LMICs

137 LMICs

Phase III

Telephone and

face-to-face interviews

Phase I

Desk review

Phase II

Online Survey

**Antenatal Care Policy and Targets**

Based on Phase I (the desk review), information on the minimum number of recommended antenatal visits contained within the ANC policy was available for 122/137 (89%) countries.

Based on Phase II (the online survey), 88/95 (93%) countries provided information on minimum number of recommended ANC visits. Among these 88 countries, 15 (17.0%) recommended eight or more visits in line with the new WHO recommendation, while 15 (17.0%) countries recommended between five and seven visits.

Countries with a policy recommending >4 ANC visits were more likely to have higher PAB coverage (>=90% vs<90%, Fisher’s exact P-value=0.020). A policy of >4 ANC visits was also more common among group 4 (high potential) countries (Fisher’s exact P-value <0.001) and less common among group 2 (limited potential) countries (Fisher’s exact P-value 0.001).

**Figure 2** Percent of countries with a policy of >4 ANC visits. Data from online survey among 88 countries.

%

Group 1 = very limited potential to protect mothers and young children against vaccine-preventable diseases, Group 2 = limited potential, Group 3 = moderate potential, Group 4 = high potential, PAB = protection at birth

Fisher’s Exact P-values: \* <0.05, \*\* <0.01 \*\*\* <0.001

**Antenatal care service delivery including number of visits, timing of visits and outreach**

Although nearly all countries had a policy on the recommended minimum number of visits during pregnancy, few countries (12/26 countries responding to the telephone interview) were able to provide data on the proportion of women who attended a predefined number of visits including the respective timing of these visits. The number of women never accessing ANC services was considerable among countries with very limited to limited potential to protect mothers and children from vaccine preventable diseases, 35% and 7% respectively (Figure 3).

**Figure 3** ANC visits, by country group (telephone survey, N=26)

%

Information about the proportion of women with at least one ANC visit in the third trimester was available from only 8/26 countries that participated in the telephone interview and reported rates ranging from 10 to 98 percent.

Importantly, countries recommending >4 antenatal visits were more likely to have high performance for maternal tetanus immunization defined as PAB >90% (p=0.02) and were more likely to be group 4 countries (high potential for protection of mothers and their young children from vaccine-preventable infections) (p=0.001).

All countries provided ANC services at fixed health facilities. Government outreach programmes were offered in 55/95 (57.9%) countries, including ANC services. This was more common among group 2 (limited protection) countries (Fisher’s exact P-value 0.078) and less in group 4 (high potential, p-value 0.067), but the difference was only marginally significant (Table 1). There was no association with PAB coverage.

**Table 1** Government outreach programmes offering ANC. Data from online survey, 95 countries.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Outreach, ANC** | **PAB<90%** | **PAB>=90** | **Group 1** | **Group 2** | **Group 3** | **Group 4** | **Total** |
| No | 18 (40) | 14 (37.8) | 6 (54.5) | 9 (28.1) | 10 (38.5) | 15 (57.7) | 40 (42.1) |
| Yes | 27 (60) | 23 (62.2) | 5 (45.5) | 23 (71.9) | 16 (61.5) | 11 (42.3) | 55 (57.9) |
|  Total | 45 (100) | 37 (100) | 11 (100) | 32 (100) | 26 (100) | 26 (100) | 95 (100) |
| Fisher's exact P-value |  | 1 | 0.518 | 0.078 | 0.816 | 0.067 |  |

More detailed information about the provision of outreach services was available from the telephone interviews with 26 countries. Among the countries participating in the telephone interviews, six countries provided mobile or outreach services specifically for ANC; in 8 countries ANC was included in other outreach activities, and 7 countries provided both. During country visits, wide variation was observed in the content and frequency of outreach ANC services between countries and within a given country. Additionally, the majority of ANC outreach in countries visited provided a limited package of ANC services, including some or all of the following elements: blood pressure measurement, iron and folic acid supplementation, malaria prophylaxis (where applicable), counselling, prevention of mother-to-child transmission of HIV and referral of women to the nearest health facility for laboratory testing.

**ANC service package and quality of antenatal care**

According to the telephone interviews 14/22 (63.6%) countries provided at least 11 different ANC interventions in their ANC service package. Four countries didn’t respond to the question. The three most common services offered by more than 90% of the health facilities visited, were iron and folic acid supplementation, dietary counselling, and screening for HIV. The country visits revealed a higher number of services offered in ANC in high potential countries (group 4 *P*‑value from Wilcoxon rank sum test = 0.005).

The existence and functioning of the ANC referral systems was explored in both the telephone interviews with 26 countries and the visits to 96 facilities during the country visits. National level programme managers from 25/26 countries that provided information through the telephone interviews reported having a functional ANC referral system in place for high risk or complicated deliveries. Of the 96 facilities visited, 92/96 (95.8%) reported having a system in place for referring pregnant women to a higher level of care. The four facilities that did not report referring women were themselves reference hospitals and, thus, received but did not initiate referrals.

**Factors affecting effective ANC coverage and quality**

Most countries responding to the telephone interviews (23/24; 95.8%) reported that funding for ANC was dependent primarily upon the national budget, while 12/24 (50%) countries also benefitted from external donor funding for ANC (Figure 4). Overall, one in five countries indicated that ANC services were partly funded by out-of-pocket payments.

**Figure 4** Percentage of countries reporting different ANC funding sources, information from telephone interviews (26 countries, 2 missing answers)

%

The online survey in 95 countries provided data on user-fee exemptions for ANC and for maternal tetanus immunization. In 72/95 countries (75.8%), pregnant women were exempt from ANC user fees, and in all but one country, maternal tetanus immunization was free. In 12/95 (12.6%) countries user fee exemptions for ANC were in place only for some groups in the population and in 11/95 (11.6%) countries, no user-fee exemptions existed. The imposition of user fees for antenatal care services was significantly associated with lower PAB coverage (Fisher’s exact p-value 0.037).

**Disease Surveillance**

Passive surveillance was the most common form of disease surveillance performed (Figure 5). The morbidity and mortality indicators, which were recorded, differed between countries (Table 2). According to the online survey, most common were surveillance for neonatal tetanus (91/95; 96%) and maternal deaths (84/95; 88%). Maternal and neonatal deaths were less often recorded in group 1 countries (Fisher’s exact P-value 0.003 and 0.045, respectively). Surveillance for congenital rubella, neonatal deaths and neonatal sepsis was less common overall, but more common in group 4 countries. In terms of private facilities reporting cases of tetanus, 16/26 (62%) countries confirmed that they report tetanus cases.

**Figure 5** Percent of countries performing different types of disease surveillance for maternal and neonatal tetanus, data from online survey in 95 countries

%

**Table 2** Disease surveillance (online survey, 95 countries)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **a -Neonatal tetanus** |  |  |  |  |  |  |
|  | **PAB<90%** | **PAB>=90** | **Group 1** | **Group 2** | **Group 3** | **Group 4** | **Total** |
| No | 2 (4.4) | 0 (0) | 1 (9.1) | 0 (0) | 1 (3.8) | 2 (7.7) | 4 (4.2) |
| Yes | 43 (95.6) | 37 (100) | 10 (90.9) | 32 (100) | 25 (96.2) | 24 (92.3) | 91 (95.8) |
|  | 45 (100) | 37 (100) | 11 (100) | 32 (100) | 26 (100) | 26 (100) | 95 (100) |
| Fisher's exact |  | 0.499 | 0.394 | 0.297 | 1.000 | 0.301 |  |
| **b -Congenital rubella syndrome** |  |  |  |  |  |
|  | **PAB<90%** | **PAB>=90** | **Group 1** | **Group 2** | **Group 3** | **Group 4** | **Total** |
| No | 22 (48.9) | 9 (24.3) | 7 (63.6) | 14 (43.8) | 8 (30.8) | 4 (15.4) | 33 (34.7) |
| Yes | 23 (51.1) | 28 (75.7) | 4 (36.4) | 18 (56.3) | 18 (69.2) | 22 (84.6) | 62 (65.3) |
|  | 45 (100) | 37 (100) | 11 (100) | 32 (100) | 26 (100) | 26 (100) | 95 (100) |
| Fisher's exact |  | **0.039** | **0.045** | 0.254 | 0.809 | **0.016** |  |
| **c -Neonatal sepsis** |  |  |  |  |  |  |
|  | **PAB<90%** | **PAB>=90** | **Group 1** | **Group 2** | **Group 3** | **Group 4** | **Total** |
| No | 35 (77.8) | 25 (67.6) | 9 (81.8) | 27 (84.4) | 16 (61.5) | 13 (50) | 65 (68.4) |
| Yes | 10 (22.2) | 12 (32.4) | 2 (18.2) | 5 (15.6) | 10 (38.5) | 13 (50) | 30 (31.6) |
|  | 45 (100) | 37 (100) | 11 (100) | 32 (100) | 26 (100) | 26 (100) | 95 (100) |
| Fisher's exact |  | 0.327 | 0.493 | **0.020** | 0.459 | **0.026** |  |
| **d. -Neonatal deaths** |  |  |  |  |  |  |
|  | **PAB<90%** | **PAB>=90** | **Group 1** | **Group 2** | **Group 3** | **Group 4** | **Total** |
| No | 16 (35.6) | 4 (10.8) | 5 (45.5) | 9 (28.1) | 5 (19.2) | 1 (3.8) | 20 (21.1) |
| Yes | 29 (64.4) | 33 (89.2) | 6 (54.5) | 23 (71.9) | 21 (80.8) | 25 (96.2) | 75 (78.9) |
|  | 45 (100) | 37 (100) | 11 (100) | 32 (100) | 26 (100) | 26 (100) | 95 (100) |
| Fisher's exact |  | **0.011** | **0.050** | 0.288 | 1.000 | **0.011** |  |
| **e -Maternal deaths** |  |  |  |  |  |  |
|  | **PAB<90%** | **PAB>=90** | **Group 1** | **Group 2** | **Group 3** | **Group 4** | **Total** |
| No | 8 (17.8) | 3 (8.1) | 5 (45.5) | 3 (9.4) | 2 (7.7) | 1 (3.8) | 11 (11.6) |
| Yes | 37 (82.2) | 34 (91.9) | 6 (54.5) | 29 (90.6) | 24 (92.3) | 25 (96.2) | 84 (88.4) |
|  | 45 (100) | 37 (100) | 11 (100) | 32 (100) | 26 (100) | 26 (100) | 95 (100) |
| Fisher's exact |  | 0.330 | **0.003** | 0.745 | 0.722 | 0.279 |  |

**Discussion**

The results from this MIACSA project in low- and middle-income countries demonstrate that for maternal tetanus immunization, the majority of countries despite having a policy on recommended number of ANC visits, had yet to implement the WHO guidelines recommending eight antenatal contacts (18). Importantly, countries recommending >4 antenatal visits were more likely to have high performance for maternal tetanus immunization defined as PAB >90% and were more likely to be group 4 countries (high potential for protection of mothers and their young children from vaccine-preventable infections).

If future maternal vaccines are to be delivered to pregnant women via the ANC platform then ANC service delivery components including the number of contacts and timing of contacts are important. Some maternal vaccines may require administration during particular gestational windows, such as RSV vaccine (clinicalTrials.gov NCT02624947) so a system’s capacity to record visit timing is important for identifying gaps and targeting campaigns to maximise attendance at recommended time frames to optimise implementation of maternal immunization during antenatal care. The WHO antenatal care guidelines concentrate most of the 8 recommended contacts in the third trimester. Indicators about the frequency of visits are frequently collected, but the findings from the MIACSA project highlight that information about the timing of ANC visits by trimester is rarely available and needs to be included in future monitoring efforts, would new maternal vaccines require a specific time window for administration.

Access to ANC services for all pregnant women is a priority to reduce perinatal and maternal mortality. Transitioning to eight visits will likely help reduce the missed opportunities for vaccination and other interventions due to increased contacts with pregnant women. Early ANC contact is essential to help establish gestational age more accurately, while more frequent visits in the latter part of the pregnancy may assist with immunization coverage and reducing stillbirths (23, 24). Populations challenged by suboptimal access early in pregnancy (some due to geographical remoteness or women not recognising the need for care early in pregnancy) provide additional challenges to antenatal care service delivery.

Furthermore, few countries reported the proportion of women who attended at particular trimesters and the actual timing of contacts, which is important data required for implementation of additional maternal vaccines, particularly if they are to be administered within a specific gestational window. Given the potential importance of accurately estimating gestational age, and potentially narrow gestational windows for future maternal vaccines such as RSV, it is crucial that policy makers and those involved in implementation of new vaccines understand the relevance of this data, and invest in and build robust systems for capturing this data.

Whilst building robust systems to capture data on timing and number of antenatal contacts, consideration should be given to a coordinated approach across information systems. In-particular, improvements in tracking, reporting, linkage of mother and child records, and surveillance systems for maternal and neonatal morbidity and mortality would enable planning for the introduction of additional maternal vaccines in the future.

Uncertainty about assessing quality of antenatal care notwithstanding, the issue of out-of-pocket expenses for women is relevant to the quality of antenatal care and attendance for the recommended minimum number of antenatal visits. The presence of user fees was significantly associated with lower PAB coverage. This is likely because user fees may be a disincentive for women to access healthcare services. If increased utilisation of antenatal care services is required to maximise the opportunities for women to receive maternal vaccines in addition to tetanus in the future, then any disincentives such as out of pocket expenses need to be addressed. In addition, hidden costs for women such as transport to and from the facilities and long waiting times may further discourage utilization of antenatal care services. In the MIACSA project, out of pocket expenses did not necessarily apply to vaccine but to other antenatal care services such as pathology or ultrasound as well as cost for transportation. In all but one case, maternal immunization in the public system incurred no cost to the woman. However, the free cost of the vaccine was undermined in instances when the woman accessed the vaccine through ANC services for which there were out-of-pocket expenses.

A well-functioning disease surveillance system for both maternal and neonatal mortality and morbidity is crucial to inform the need and performance of any existing or future vaccine programme. Based on the findings from the MIACSA project there is significant variability, depending on the setting, on the range of diseases covered by surveillance and often a complete absence of a surveillance system for outcomes such as stillbirth. These gaps and inconsistencies identified by the MIACSA project highlight the need to strengthen capacity for both maternal and neonatal disease surveillance in parallel with strengthening antenatal care service delivery. These systems are essential to the planning, implementation and the evaluation of any future public health initiative such as a new maternal immunization programme.

The study methodology has several limitations. The different data sources used in the MIACSA project meant that inconsistencies between the different databases were observed for some quantitative and policy-related indicators. This may have been due to collection of information at different time-points, inconsistent definitions across sources, or different sampling methodologies. Besides different sources of data, inaccurate reporting cannot be fully excluded despite efforts made by the countries to validate the information provided to the study team. Another limitation was the relatively small number of countries visited, and of health facilities by country. Health facilities visited were not randomly selected but were assigned by the Ministries of Health. They are not therefore necessarily representative of the entire country but rather reflect a potentially higher-performing part of the health system within a particular country.

**Conclusion**

The MIACSA project has identified aspects of maternal tetanus immunization that need to be strengthened and gaps that need to be addressed to inform the introduction of additional maternal vaccines particularly into antenatal care services. Specific recommendations arising from the MIACSA project include;

* Increasing the number of countries adopting the current WHO recommendation for 8 antenatal contacts thereby increasing opportunities for vaccination during pregnancy
* Introducing record keeping systems that are able to identify the proportion of women who attend per trimester of pregnancy
* Introducing record keeping systems that are able to identify timing of visits during pregnancy (not just total number)
* Reducing any associated costs for ANC and supporting user fee exemptions for all vulnerable women
* Introducing maternal and neonatal disease surveillance systems (including for stillbirth) consistently across all LMICs

It is hoped that with implementation of these recommendations a stronger ANC system will prevail leading to improved utilisation of ANC services. This in turn provides greater opportunities to vaccinate pregnant women with the currently recommended maternal vaccines and a robust platform for the introduction of new maternal vaccines in the future. **References**

1. World Health Organization. Trends in Maternal Mortality: 1990-2015. Estimates by WHO, UNICEF, UNFRA, World Bank Group and the United National Population Division. World Health Organization 2015.

2. UNICEF. Neonatal Mortality [accessed 2019 June 8]. <https://data.unicef.org/topic/child-survival/neonatal-mortality/>

3. Lawn JE, Blencowe H, Waiswa P, Amouzou A, Mathers C, Hogan D et al. Stillbirths: rates, risk factors, and acceleration towards 2030 Lancet 2016; 387: 587–603

4. United Nations. Sustainable development goals [accessed June 3 2019]. <https://www.un.org/sustainabledevelopment/sustainable-development-goals/>

5. United Nations. Sustainable development goals [accessed June 3 2019]. <https://www.un.org/sustainabledevelopment/health/>

6. Liu L, Oza S, Hogan D, Chu Y, Perin J, Zhu J, Lawn JE, Cousens S, Mathers C, Black RE. Global, regional, and national causes of under-5 mortality in 2000–15: an updated systematic analysis with implications for the Sustainable Development Goals. Lancet. 2016;388:3027–35. doi:10.1016/S0140-6736(16)31593-8.

7. Hug L, Alexander M, You D, Alkema L, on behalf of the UN Inter-agency Group for Child Mortality Estimation. National, regional and global levels and trends in neonatal mortality between 1990 and 2017, with scenario-based projections to 2030: a systematic analysis. Lancet Glob Health 2019;7:e710-20

8. World Health Organization. Immunization, Vaccines and Biologicals. Tetanus. [accessed June 3 2019]. <https://www.who.int/immunization/diseases/tetanus/en/>

9. World Health Organization. The weekly epidemiological record. Geneva; 2012. p201-216

10. Centers for Disease Control and Prevention. Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap) in Pregnant Women — Advisory Committee on Immunization Practices (ACIP), 2012 2013.

11. Public Health England. Pertussis Vaccination Programme for Pregnant Women update: Vaccine coverage in England, July to September 2017. London, UK: Public Health England publications; 2017.

12. Pertussis in Argentina. 2017. (Accessed June 7, 2019, at <https://www.cdc.gov/pertussis/countries/lapp-argentina.html>.)

13. Maertens K, Braeckman T, Top G, Van Damme P, Leuridan E. Maternal pertussis and influenza immunization coverage and attitude of health care workers towards these recommendations in Flanders, Belgium. Vaccine 2016;34:5785-91.

14. Public Health Agency of Canada. Update on Immunization in Pregnancy with Tetanus Toxoid, Reduced Diphtheria Toxoid and Reduced Acellular Pertussis (Tdap) Vaccine. Ontario, Canada 2018.

15. Immunisation for Pregnant Women. Ministry of Health, 2018. (Accessed June 7 2019, at <https://www.health.govt.nz/your-health/healthy-living/immunisation/immunisation-pregnant-women>)

16. UNICEF global databases 2016. (accessed June 14, 2019 at <https://data.unicef.org/topic/maternal-health/antenatal-care/>)

17. Moller A-B, Petzold M, Chou D and Say L. Early antenatal care visit: a systematic analysis of regional and global levels and trends of converage from 1990-2013. The Lancet Global Health Vol 5 (10); PE977-E983 Oct 1 2017

18. World Health Organization. WHO recommendations on antental care for a positive pregnancy experience. 2016 (<https://www.who.int/reproductivehealth/publications/maternal_perinatal_health/anc-positive-pregnancy-experience/en>)

19. Shi T, McAllister DA, O’Brien KL, Simoes EAF, Madhi SA, Gessner BD, Polack FP et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. The Lancet 2017;390:946-58.

20. Seale AC, Bianchi-Jassir F, Russell NJ, Kohli-Lynch M, Tann CJ, Hall J et al. Estimates of the Burden of Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths and Children. Clin Infect Dis 2017 Nov 6;65 (suppl\_2):S200-S219

21. Roos N, Lambach P, Mantel C, Mason E, Muñoz F, Giles M, Moran A, Hombach J, Diaz T, MIACSA expert advisory panel group. Maternal Immunization and Antenatal

Care Situation Analysis (MIACSA) study protocol: a multiregional, cross sectional

analysis of maternal immunization delivery strategies to reduce maternal and neonatal morbidity and mortality. BMJ Open 2019

22. McCutcheon AL. (1987) *Latent class analysis,* Newbury Park, California: Sage Publications.

23. Lavin T and Pattison RC. Does antenatal care timing influence stillbirth risk in the third trimester? A secondary analysis of perinatal death audit data in South Africa. BJOG 2018 Jan;125(2):140-147

24. Beauclair R, Petro G, Myer L. The association between timing of initiation of antenatal care and stillbirth: a retrospective cohort study of pregnant women in Cape Town, South Africa. BMC Pregnancy Childbirth 2014 June 13;14:204